SBC Medical Q4 2025 Revenue Falls, Net Income Surges
KUALA LUMPUR, March 30 (Bernama) -- SBC Medical Group Holdings Incorporated (SBC Medical) reported an 11 per cent year-on-year decline in fourth-quarter (Q4) revenue to US$40 million for the three months ended Dec 31, 2025, following restructuring and changes to its franchise model. (US$1=RM4.01)
However, the company’s net income for the quarter rose 117 per cent to US$14 million, reflecting improved profitability despite weaker top-line performance.
In a statement, its Chairman and Chief Executive Officer, Yoshiyuki Aikawa said the results reflect a business in transition, citing restructuring in 2024 and revised franchise fee arrangements implemented in April 2025 as key drivers of the revenue decline.
Earnings per share increased 133 per cent to US$0.14, although earnings before interest, taxes, depreciation and amortisation (EBITDA) declined 35 per cent to US$14 million, with margins narrowing to 34 per cent.
Operational indicators showed resilience, with average revenue per customer recovered to US$316, an 11 per cent increase year-over-year—a meaningful inflection after a period of gradual decline and one that reflects the early impact of its pricing and customer engagement initiatives.
The company ended the year with 283 franchise locations and 6.6 million customers over the past 12 months, both higher than a year earlier.
Looking ahead, SBC Medical plans to expand its dermatology-focused multi-brand strategy, grow its non-aesthetic healthcare segment and strengthen its international footprint.
-- BERNAMA